| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Dr. Reddy's Laboratories Ltd$11.77
-0.02 (-0.17%)
B 60Pipeline Score Fair Value Pharma · Commercial
Market Cap
11.40 B
EPS
0.59
P/E Ratio
23.14 $
Value Trade
17.45 M
-0.95 %
Week
6.17 %
1 Month
-5.16 %
3 Month
-2.02 %
6 Month
-6.17 %
5 Year
1,243.87 %
All Time
Cash Data
Cash Position
12.35 K
Monthly Burn
12.35 K
Runway
12,345 mo
Overview
Volume
3.62 M
52 Week Range
12.19 - 16.17
% held by Insiders
0 %
% held by Institutions
14.87 %
Enterprise Value
11.32 B
Total Shares
832.56 M
Short %
-
Float Shares
832.56 M
Company Description
locked
Upcoming Catalyst
Catalyst Timeline
Dated clinical, regulatory & corporate events for Dr. Reddy's Laboratories Ltd
641Total events
3Upcoming
187Tier-1 (high impact)
2015 – 2026Coverage
Upcoming catalysts 2
TBD
T2Trial Initiation
Subscribe to view catalyst details
TBD
T1EU Approval
Subscribe to view catalyst details
Event history 2
TBD
▲Product LaunchPost-Market
Subscribe to view catalyst details
TBD
◆R&D DayPresentation
Subscribe to view catalyst details
Past FDA Catalysts & PDUFA Decisions
| Date | Drug | Catalyst | Stage | Outcome | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|---|
2025-05-30 | Phenylephrine Hydrochloride In 0.9% Sodium Chloride (phenylephrine hydrochloride) | PDUFA Date | PDUFA | Approved | – | – | – |
2025-05-30 | Phenylephrine Hydrochloride In 0.9% Sodium Chloride (phenylephrine hydrochloride) | PDUFA Date | PDUFA | Approved | – | – | – |
2025-05-30 | Phenylephrine Hydrochloride In 0.9% Sodium Chloride (phenylephrine hydrochloride) | PDUFA Date | PDUFA | Approved | – | – | – |
Drug Pipeline Intelligence
B60
Pipeline Score $12.8B
Pipeline ValueFair Value
Valuation Signal65
Drugs Scored1.1x
rNPV / MCap Top 89%
Mid Cap (rank 101 of 913)
Percentile RankDr. Reddy's Laboratories Ltd holds a solid B-grade pipeline (60/100), with $15.2B risk-adjusted pipeline value, led by DFD06- in Chronic Stable Plaque Psoriasis (Phase 3).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| DFD06 Small molecule | Psoriasis | Phase 3 | NCT02131324 | 64% | $5.5B | COMPLETED | 317 | - | - | Aug 11, 2016 | - | May 18, 2018 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
AUR112 | relapsed/refractory lymphoid malignancies | Phase 1 | 2025-12-02 | overall response rate: 63.6%; efficacy evaluable population: 63.6%; intent to treat group: 58.3%; patients evaluable for safety: 13; patients evaluable for efficacy: 11 Read More | Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies Read More | |
AUR112 | relapsed/refractory lymphoid malignancies | Phase 1 | 2025-12-02 | overall response rate: 63.6%; efficacy evaluable population: 63.6%; intent to treat group: 58.3%; patients evaluable for safety: 13; patients evaluable for efficacy: 11 Read More | Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies Read More | |
AUR112 | relapsed/refractory lymphoid malignancies | Phase 1 | 2025-12-02 | overall response rate: 63.6%; efficacy evaluable population: 63.6%; intent to treat group: 58.3%; patients evaluable for safety: 13; patients evaluable for efficacy: 11 Read More | Aurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies Read More |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in RDY
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
RDY Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-08-21 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
RDYDr. Reddy’s Laboratories Limited Announces Filing of Annual Report on Form 20-F
Dr. Reddy's Laboratories Limited has filed its Annual Report on Form 20-F. This report is a standard requirement for foreign companies listed in the U.S. and provides detailed financial information and disclosures. The filing reflects the company's commitment to transparency and compliance with regulatory standards.
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills Hyderabad - 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.c
Dr. Reddy's Laboratories announced the first-to-market launch of Bosutinib Tablets 400mg, a generic equivalent of Bosulif, in the United States, on June 13, 2026. This product launch marks an expansion of Dr. Reddy’s oncology portfolio, made possible through collaboration with MSN Laboratories. The launch positions Dr. Reddy's for a significant role in the oncology market, as Bosulif recorded approximately $253.8 million in U.S. sales within the latest 12-month period. The exclusive marketing rights held by Dr. Reddy's are expected to enhance patient access to affordable and high-quality cancer treatment.
Read more →RDYDr. Reddy's Laboratories Ltd . 8-2-337, Road No. 3, Banjara Hills Hyderabad - 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys.
Dr. Reddy's Laboratories has announced the allotment of 12,100 equity shares to eligible employees as part of its Employee Stock Options Scheme. This issuance follows the exercise of stock options under the Dr. Reddy's Employees Stock Option Scheme, 2002 and the ADR Stock Option Scheme, 2007. The shares have a par value of Re. 1 each and were allotted on June 5, 2026. This move reflects the company's commitment to employee participation and follows the regulatory guidelines stipulated by SEBI.
Read more →RDYNational Stock Exchange of India Ltd.
Dr. Reddy's Laboratories Limited announced that the Board of Directors will consider the proposal for recommending the final dividend for the fiscal year 2025-26. This follows an earlier communication made on March 23, 2026. The decision regarding the dividend will be deliberated in an upcoming board meeting. No specific details about the dividend amount or other financial aspects were disclosed in the announcement.
Read more →RDYDr. Reddy’s Announces the First-to-Market Launch of Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7% (OTC), the Generic Equivalent of Extra-Strength Pataday® Once Daily Relief, in the U.S.
Dr. Reddy's Laboratories has launched the first-to-market generic equivalent of Extra Strength Pataday, known as Olopatadine Hydrochloride Ophthalmic Solution USP, 0.7%, in the U.S. This over-the-counter product is designed to provide temporary relief from itchy eyes caused by allergens. The launch enhances Dr. Reddy's existing OTC eye-care portfolio and reflects the company's commitment to offering affordable healthcare solutions.
Read more →RDYReview Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors of Dr. Reddy's Laboratories Limited Results of Review of Interim Financial Statements We have reviewed the accompa
Dr. Reddy's Laboratories Limited received a positive review report from its independent registered public accounting firm concerning its interim financial statements as of December 31, 2025. The review indicated that the statements are in conformity with relevant accounting standards and require no material modifications. This follows a prior unqualified audit opinion on the company’s consolidated financial statements, reinforcing the integrity of their financial reporting.
Read more →RDYAurigene Oncology Limited Announces Encouraging Initial Data From 1st Two Cohorts of Phase 1 Study of AUR112, an Oral Small Molecule Inhibitor of MALT1, in Relapsed/Refractory Lymphoid Malignancies
Aurigene Oncology Limited has reported encouraging initial results from the first two cohorts of its Phase 1 trial for AUR112, an oral MALT1 inhibitor targeting relapsed/refractory lymphoid malignancies. The drug demonstrated a 63.6% overall response rate and was well tolerated by patients. The company plans to expand the study to include additional lymphoid malignancies based on these positive findings.
Read more →RDYReport of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors of Dr. Reddy's Laboratories Limited Results of Review of Interim Financial Statements We have reviewed the accompanying c
Dr. Reddy's Laboratories Limited underwent a review of its interim financial statements for the period ending September 30, 2025. The reviewing accounting firm reported no material modifications necessary for conformity with international standards. The previous audit reaffirmed the financial position's accuracy, supporting the company's transparency and financial health.
Read more →RDYSECURITIES AND EXCHANGE COMMISSION
Dr. Reddy's Laboratories has filed a report as a foreign private issuer with the Securities and Exchange Commission under the Securities Exchange Act of 1934. The report indicates compliance with filing regulations, and the submission includes information pertinent to the registrant's activities and requirements. The filing was signed by K Randhir Singh, the Company's Secretary, and is dated October 24, 2025. This document serves as an important update in the company's regulatory obligations.
Read more →RDYDr. Reddy's Laboratories Ltd . 8-2-337, Road No. 3, Banjara Hills Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com
Dr. Reddy's Laboratories Ltd. has announced a publication regarding the transfer of unclaimed dividends and associated equity shares to the Investor Education and Protection Fund (IEPF). This action is in compliance with Section 124(6) of the Companies Act, 2013. The announcement was published on May 28, 2025, in the Business Standard and Nava Telangana newspapers. The notification serves as an important record for shareholders.
Read more →RDYDr. Reddy's Laboratories Ltd . 8-2-337, Road No. 3, Banjara Hills Hyd erabad - 500 034, Telangana, India CIN: L85195TG1984PLC004507 Tel: + 91 40 4900 2900 Fax: + 91 40 4900 2999 Email: mail@drreddys.com Web: www.drreddys
Dr. Reddy's Laboratories Ltd. has announced that it will release its Q4 and full-year results for FY25 on May 9th, 2025. The earnings call is scheduled for the same day, aimed at discussing the company's financial performance. Investors and stakeholders will have access to the results through various mediums, including the company’s website. This release reflects Dr. Reddy's commitment to maintaining transparency and engagement with its shareholders.
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.co
Dr. Reddy's Laboratories reported strong financial results for Q3FY25, achieving a 16% year-over-year growth in revenues amounting to approximately $977 million, aided by the consolidation of the Nicotine Replacement Therapy business. The company's EBITDA margin stood at 27.5%, indicating stable operational performance, while net profit after tax experienced a growth of 2% year-over-year. However, the company noted some challenges, such as a dip in revenue quarter-over-quarter and rising SG&A expenses linked to acquisitions and logistics costs. Additionally, it launched significant new products aimed at enhancing care in India.
Read more →RDYDR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Richa Periwal AISHWARYA SITHARAM richaperiwal@drreddys.com aishwaryasitha
Dr. Reddy's Laboratories Ltd. reported consolidated financial results for Q1FY25, highlighting a 14% increase in revenues compared to the previous year, driven primarily by growth in its generics business. The company's gross margin rose to 60.4%, reflecting improved operational efficiency. However, profit after tax saw a slight decline of 1% YoY, despite an overall positive growth trajectory in revenue and EBITDA. The management emphasized ongoing investments in biologics and consumer healthcare to maintain this momentum and enhance future value creation.
Read more →RDYDr. Reddy's Laboratories Ltd 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 0 34, Telangana, India. CIN: L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com
Dr. Reddy's Laboratories Limited has published a newspaper advertisement regarding the notice of its 40th Annual General Meeting and e-voting information. This announcement is made in compliance with Regulation 47 of the Securities and Exchange Board of India. The advertisement was published in Business Standard and Nava Telangana, indicating the company's ongoing commitment to transparency and shareholder engagement.
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 0 34, Telangana, India. CIN: L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com
Dr. Reddy's Laboratories announced a definitive agreement to acquire the Nicotinell brand and related portfolio from Haleon plc for GBP 500 million. This strategic acquisition is in line with the company's focus on enhancing its consumer healthcare segment. Nicotinell is a leading brand in Nicotine Replacement Therapy (NRT) and generated revenues of GBP 217 million in 2023. The deal will be funded through internal accruals, and operations are expected to transition smoothly by the closing date in early Q4 of 2024.
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com
Dr. Reddy's Laboratories has announced its participation in upcoming investor conferences as per SEBI regulations. The company will engage with institutional investors on February 9, 2024, in a virtual meeting hosted by Nirmal Bang Group. Schedules for these meetings may change due to unforeseen circumstances. This initiative indicates the company's commitment to maintaining transparency with its investors.
Read more →RDYDR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Richa Periwal richaperiwal@drreddys.com AISHWARYA SITHARAM aishwaryasitha
Dr. Reddy's Laboratories Ltd. announced its financial results for Q3 and 9M FY24, showing an increase in revenues of 7% YoY for Q3, reaching ₹72,148 million, and a 14% YoY growth for the first nine months. The company's EBITDA for Q3FY24 was ₹21,107 million with margins at 29.3%. Despite strong overall growth in sales and profit before tax up by 12% YoY, profit after tax saw a decline of 7% QoQ. The results reflect continued investment in new products and operational efficiency to capture market share in the U.S. and Europe.
Read more →RDYDR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. RICHA PERIWAL richaperiwal@drreddys.com USHA IYER ushaiyer@drreddys.com D
Dr. Reddy's Laboratories Ltd. reported its consolidated financial results for Q2 FY24, showing a revenue of Rs. 68,802 million, an increase of 9% compared to the previous year. The company achieved its highest ever profits, with a profit after tax of Rs. 14,800 million, up 33% year-over-year. CEO G V Prasad highlighted market share gains in the US generics segment and growth in Europe as key contributors to this success. The company plans to continue bolstering its pipeline through both organic efforts and business development strategies.
Read more →RDYDr. Reddy's Laboratores Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com
Dr. Reddy's Laboratories disclosed ongoing legal proceedings as per SEBI regulations, including direct tax cases and other litigations. While the company has successfully resolved some tax disputes, it is currently involved in various complex legal challenges. These include ongoing appeals against tax demand notices and other claims which may have uncertainties in financial impact. However, the company believes these legal matters will not materially harm its financial stability.
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel :+9140 4900 2900 Fax :+9140 4900 2999 Email :mail@drreddys.com www.drreddys.com
Dr. Reddy's Laboratories reported strong financial performance for the first quarter of FY2024, with consolidated revenues reaching Rs. 6,738 crores (approximately $821 million), reflecting a year-over-year growth of 29%. Key highlights include significant gains in EBITDA, a healthy cash generation leading to a surplus, and advances in product approvals, including a biosimilar candidate accepted by regulatory bodies. The company achieved notable revenue increases across its generics business in various geographical regions including the US and Europe.
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com
Dr. Reddy's Laboratories Ltd. has released its unaudited financial results for the quarter ending June 30, 2023. The results were disclosed in compliance with the Securities and Exchange Board of India regulations, and details were published in major newspapers such as Business Standard and Andhra Prabha on July 27, 2023. This announcement serves as an official record for stakeholders and investors.
Read more →RDYDr. Reddys Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com
Dr. Reddy's Laboratories Limited has shared the audio recording of its earnings call for the quarter ended June 30, 2023. This call took place on July 26, 2023, and the company has complied with the Regulation 30 of the Securities and Exchange Board of India. A web link to the recording has been provided for investors and stakeholders.
Read more →RDYDR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, RICHA PERIWAL USHA iyer Hyderabad - 500034. Telangana, India. richaperiwal@drreddys.com ushaiyer@drreddys.com D
Dr. Reddy's Laboratories Ltd. reported its financial results for Q1 FY24, showing a consolidated revenue of Rs. 67,384 million, which is a 29% year-over-year increase. The company also noted significant improvements in profit metrics, with a profit before tax up 26% YoY and profit after tax up 18% YoY. The gross margin has strengthened to 58.7%, indicating better cost management and margin expansion. Overall, these results reflect robust performance, driven by growth in their US generics business and market share gains.
Read more →RDYDr. Reddy's Laboratorie Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com
Dr. Reddy's Laboratories Limited has announced a Board Meeting scheduled for July 26, 2023, to discuss and approve the unaudited financial results for the quarter ending June 30, 2023. The company has also informed that the trading window will be closed from June 24, 2023, until July 28, 2023, following SEBI regulations. This closure may imply that significant financial information will be disclosed, creating anticipation among investors.
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel: +91 40 4900 2900 Fax: +91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com
Dr. Reddy's Laboratories has announced a strong financial performance for the fiscal year 2023, achieving record sales and profit levels. The company reported a 15% increase in revenues, driven by new product launches and growth in core businesses. Notable achievements include recognition for sustainability efforts and excellence in operational efficiency. The earnings call provided insights into the company's strategic focus on enhancing manufacturing and R&D capabilities.
Read more →RDYDR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Investor relationS Media relationS Richa Periwal richaperiwal@drreddys.com USHA IYER ushaiyer@drreddys.com D
Dr. Reddy's Laboratories announced its consolidated financial results for Q3 and the first nine months of FY23, showing robust growth figures. The company reported a 27% increase in revenue year-over-year for Q3, alongside a substantial 68% rise in profit before tax. The gross margin improved to 59.2%, reflecting enhanced operational efficiency. Key markets contributing to this performance include the U.S. and Russia, which are pivotal for future growth strategies.
Read more →RDYDR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com USHA iyer ushaiyer@drreddys.com Dr. Reddy
CONTACT DR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com USHA iyer ushaiyer@drreddys.com Dr. Reddy's Q2 & H1 FY23 Financial India, October 28, 2022: Dr.
Read more →RDYDR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, AMIT AGARWAL USHA iyer Hyderabad - 500034. Telangana, India. amita@drreddys.com ushaiyer@drreddys.com Dr. Reddy
CONTACT DR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, AMIT AGARWAL USHA iyer Hyderabad - 500034. Telangana, India. amita@drreddys.com ushaiyer@drreddys.com Dr. Reddy's Q1 FY23 Financial Results Hyderabad, India, Ju
Read more →RDYDR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com USHA IYER ushaiyer@drreddys.com Dr. Reddy
CONTACT DR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com USHA IYER ushaiyer@drreddys.com Reddy's Q4 & FY22 Financial Results Hyderabad, India, May 19, 2022
Read more →RDYDR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Investor relationS Media relationS AMIT AGARWAL amita@drreddys.com USHA IYER ushaiyer@drreddys.com Dr. Reddy
CONTACT DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Investor relationS Media relationS AMIT AGARWAL amita@drreddys.com USHA IYER ushaiyer@drreddys.com Q3 & 9M FY22 Financial Results Hyderabad, India, January 28, 2022:
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel :+9140 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com
National Stock Exchange of India Ltd. New York Stock Exchange Inc. Pursuant to Regulation 29 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby intimate you that a meeting of the Board of Directors of the C
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3; Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3; Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com National Stock Exchange of India Ltd. New York Stock Excha
Read more →RDYPlease find enclosed a Press Release on
Corporate Relationship Department National Stock Exchange of India Ltd. BSE Limited "Exchange Plaza" Dalal Street, Fort Bandra-Kurla Complex, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Fax Nos.: 022-22723121 / 22723719 / 22722037 / 22722039 Fax Nos.: 022-26598120/ 26598237/
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+9140 4900 2999 Email :mail@drreddys.com www.drreddys.com
Stock Exchange of India Ltd. Transcript of the Earnings call conducted on July 27, 2021 to Regulation 30 of Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed the transcript of the Earnings call for
Read more →RDY▼ -12.4%on this newsshared move
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT
AND EXCHANGE COMMISSION Washington, D.C. 20549 REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13A-16 OR 15D-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934 Commission File Number 1-15182 REDDY'S LABORATORIES LIMITED (Translation of registrant's name into 8-2-337, Road No.
Read more →RDYDR. REDDY'S LABORATORIES LTD. CONTACT 8-2-337, Road No. 3, Banjara Hills, Investor relationS Media relationS Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com (Ph: +91-98661 74248) USHA iyer ushaiyer@
DR. REDDY'S LABORATORIES LTD. CONTACT 8-2-337, Road No. 3, Banjara Hills, Investor relationS Media relationS Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com (Ph: +91-98661 74248) USHA iyer ushaiyer@drreddys.com ( Ph: +91-99874 44106 ) Reddy's Q4 & FY21 Fina
Read more →RDYDR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com (Ph: +91-40-4900 2135) APARNA TEKURI apar
CONTACT DR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com (Ph: +91-40-4900 2135) APARNA TEKURI aparnatekuri@drreddys.com (Ph: +91-40-4900 2446) Reddy's Q3 &
Read more →RDYDR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, AMIT AGARWAL APARNA TEKURI Hyderabad - 500034. Telangana, India. amita@drreddys.com aparnatekuri@drreddys.com (
CONTACT DR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, AMIT AGARWAL APARNA TEKURI Hyderabad - 500034. Telangana, India. amita@drreddys.com aparnatekuri@drreddys.com (P h : +91-40-4900 2135) (P h : +91-40-4900 2446) Q1 FY21
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com
Corporate Relationship Department National Stock Exchange of India Ltd. BSE Limited "Exchange Plaza" Dalal Street, Fort Bandra-Kurla Complex, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Fax Nos.: 022-22723121 / 22723719 / Fax Nos.: 022-26598120/ 26598237/ 22722037 / 22722039
Read more →RDYThe Secretary / Executive Director
The Secretary / Executive Director National Stock Exchange of India Ltd. Pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we wish to inform you that India Ratings and Research (Ind-Ra) has assigned/affirmed the ratings
Read more →RDYPlease find enclosed a Press Release on "Dr.
Corporate Relationship Department National Stock Exchange of India Ltd. BSE Limited "Exchange Plaza" Dalal Street, Fort Bandra-Kurla Complex, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Fax Nos.: 022-22723121 / 22723719 / Fax Nos.: 022-26598120/ 26598237/ 22722037 / 22722039
Read more →RDYDR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com (Ph: +91-40-4900 2135) DEEP GHATAK deepgh
CONTACT DR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com (Ph: +91-40-4900 2135) DEEP GHATAK deepghatak@drreddys.com (Ph: +91-40-4900 2121) Dr. Reddy's Q3 &
Read more →RDYDR. REDDY'S LABORATORIES LTD. CONTACT 8-2-337, Road No. 3, Banjara Hills, Investor relationS Media relationS Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com (Ph: +91-40-4900 2135) MITALI SARKAR mita
DR. REDDY'S LABORATORIES LTD. CONTACT 8-2-337, Road No. 3, Banjara Hills, Investor relationS Media relationS Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com (Ph: +91-40-4900 2135) MITALI SARKAR mitali.sarkar@drreddys.com (Ph: +91-40-4900 2121) Dr. Reddy's Q
Read more →RDYReview Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors of Dr. Reddy's Laboratories Limited We have reviewed the accompanying condensed consolidated interim statement of
Review Report of Independent Registered Public Accounting Firm To the Shareholders and Board of Directors of Dr. Reddy's Laboratories Limited We have reviewed the accompanying condensed consolidated interim statement of financial position of Dr. Reddy's Laboratories Limited
Read more →RDYInvestor relationS Media relationS DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com (Ph: +91-40-4900 2135) MITALI SARKAR mita
CONTACT Investor relationS Media relationS DR. REDDY'S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com (Ph: +91-40-4900 2135) MITALI SARKAR mitali.sarkar@drreddys.com (Ph: +91-40-4900 2121) Reddy's Q1
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com 3
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com National Stock Exchange of India Limited New York Stock Ex
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com National Stock Exchange of India Ltd. New York Stock Exc
Read more →RDYDR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com (Ph: +91-40-4900 2135) MITALI SARKAR mita
CONTACT DR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. AMIT AGARWAL amita@drreddys.com (Ph: +91-40-4900 2135) MITALI SARKAR mitali.sarkar@drreddys.com (Ph: +91-40-4900 2121) Q4 & FY19 Fi
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Emil : mail@drreddys.com www.drreddys.com
National Stock Exchange of India Limited This is in reference to our letter dated February 21, 2019 enclosing the notice of Postal Ballot seeking approval of Members of the Company for continuation of directorship of Dr. Bruce L A Carter (DIN: 02331774) aged 75 years and furth
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax: +91 40 4900 2999 Emil : mail@drreddys.com www.drreddys.com
National Stock Exchange of India Ltd. New York Stock Exchange Inc. This is to inform you that the Nomination, Governance & Compensation committee of the Board of Directors of the Company has allotted 5,087 equity shares of Rs.5/- each of the Company, fully paid up, on March 1
Read more →RDYDR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, AMIT AGARWAL CALVIN PRINTER Hyderabad - 500034. Telangana, India. amita@drreddys.com calvinprinter@drreddys.com
CONTACT DR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, AMIT AGARWAL CALVIN PRINTER Hyderabad - 500034. Telangana, India. amita@drreddys.com calvinprinter@drreddys.com (Ph: +91-40-4900 2135) (Ph: +91-40-4900 2121) Q3 FY19 Fi
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com
Corporate Relationship Department National Stock Exchange of India Ltd. BSE Limited "Exchange Plaza" Dalal Street, Fort Bandra-Kurla Complex, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Fax Nos.: 022-22723121 / 22723719 / Fax Nos.: 022-26598120/ 26598237/ 22722037 / 22722039
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com
November 28, 2018 Corporate Relationship Department National Stock Exchange of India Ltd. BSE Limited "Exchange Plaza" Dalal Street, Fort Bandra-Kurla Complex, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Fax Nos.: 022-22723121 / 22723719 / Fax Nos.: 022-26598120/ 26598237/
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel: +91 40 4900 2900 Fax:+91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com Nov
Corporate Relationship Department BSE Limited Dalal Street, Fort Mumbai - 400 001 Fax Nos.: 022-22723121 / 22723719 / 22722037 / 22722039 National Stock Exchange of India Ltd. "Exchange Plaza" Bandra-Kurla Complex, Bandra (East), Mumbai - 400 051 Fax Nos.: 022-26598120 / 26598237
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com Corporate Relationship Department National Stock Exchang
Read more →RDYDR. REDDY'S LABORATORIES LTD. CONTACT 8-2-337, Road No. 3, Banjara Hills, Investor relationS Media relationS Hyderabad - 500034. Telangana, India. Saunak Savla Calvin Printer saunaks@drreddys.com calvinprinter@drreddys.c
DR. REDDY'S LABORATORIES LTD. CONTACT 8-2-337, Road No. 3, Banjara Hills, Investor relationS Media relationS Hyderabad - 500034. Telangana, India. Saunak Savla Calvin Printer saunaks@drreddys.com calvinprinter@drreddys.com (Ph: +91-40-4900 2135) (Ph: +91-40-4900 2121) Q2 & H1
Read more →RDYDr. Raddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com
Dr. Raddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com Corporate Relationship Department National Stock Exchang
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com National Stock Exchange of India Ltd. New York Stock Excha
Read more →RDYReview Report of Independent Registered Public Accounting Firm To Board of Directors and Shareholders of Dr. Reddy's Laboratories Limited We have reviewed the condensed consolidated interim statement of financial positio
Review Report of Independent Registered Public Accounting Firm To Board of Directors and Shareholders of Dr. Reddy's Laboratories Limited We have reviewed the condensed consolidated interim statement of financial position of Dr. Reddy's Laboratories Limited and subsidiaries
Read more →RDYNotice 237 NOTICE OF ANNUAL GENERAL MEETING Notice is hereby given that the 34th annual general meeting (AGM) of the members of Dr. Reddy's Laboratories Limited (CIN: L85195TG1984PLC004507) will be held on Friday, 27 Jul
NOTICE OF ANNUAL GENERAL MEETING is hereby given that the 34th annual general meeting (AGM) of the members of Dr. Reddy's Laboratories Limited (CIN: L85195TG1984PLC004507) will be held on Friday, 27 July 2018 at 9.30 am at The Ballroom, Hotel Park Hyatt, Road No. 2, Banjara Hil
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabed - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddys.co
Corporate Relationship Department National Stock Exchange of India Ltd. BSE Limited "Exchange Plaza" Dalal Street, Fort Bandra-Kurla Complex, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Fax Nos.: 022-22723121 / 22723719 / Fax Nos.: 022-26598120/ 26598237/ 22722037 / 22722039
Read more →RDYDR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Saunak Savla saunaks@drreddys.com (Ph: +91-40-4900 2135) Calvin Printer c
CONTACT DR. REDDY'S LABORATORIES LTD. Investor relationS Media relationS 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. Saunak Savla saunaks@drreddys.com (Ph: +91-40-4900 2135) Calvin Printer calvinprinter@drreddys.com (Ph: +91-40-4900 2121) Q4 and FY
Read more →RDYDr. R EDDY'S L ABORATORIES L TD . 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddy
April 10, 2018 Corporate Relationship Department National Stock Exchange of India Ltd. BSE Limited "Exchange Plaza" Dalal Street, Fort Bandra-Kurla Complex, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Fax Nos.: 022-22723121 / 22723719 / Fax Nos.: 022-26598120/ 2659823
Read more →RDYReport of Independent Registered Public Accounting Firm To the Board of Directors and Shareholders Dr. Reddy's Laboratories Limited Results of Review of Interim Financial Statements We have reviewed the accompanying cond
Report of Independent Registered Public To the Board of Directors and Shareholders Dr. Reddy's Laboratories Limited Results of Review of Interim Financial We have reviewed the accompanying condensed consolidated interim statements of financial position of Dr. Reddy's Laborat
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email : mail@drreddys.com www.drreddy.com
Corporate Relationship Department National Stock Exchange of India Ltd. BSE Limited "Exchange Plaza" Dalal Street, Fort Bandra-Kurla Complex, Bandra (East), Mumbai - 400 001 Mumbai - 400 051 Fax Nos.: 022-22723121 / 22723719 / Fax Nos.: 022-26598120/ 26598237/ 22722037 / 22722039
Read more →RDYDR. REDDY'S LABORATORIES LTD. CONTACT 8-2-337, Road No. 3, Banjara Hills, Investor relationS Media relationS Hyderabad - 500034. Telangana, India. Saunak Savla Calvin Printer CIN: L85195TG1984PLC004507 saunaks@drreddys.c
DR. REDDY'S LABORATORIES LTD. CONTACT 8-2-337, Road No. 3, Banjara Hills, Investor relationS Media relationS Hyderabad - 500034. Telangana, India. Saunak Savla Calvin Printer CIN: L85195TG1984PLC004507 saunaks@drreddys.com calvinprinter@drreddys.com (Ph: +91-40-4900 2135) (Ph: +
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com January 24, 2018 Corporate Relationship Department Nati
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com Corporate Relationship Department National Stock Exchange
Read more →RDYDr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel : + 91 40 4900 2900 Fax : + 91 40 4900 2999 Email : mail@drreddys.com www.drreddys.c
Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel : + 91 40 4900 2900 Fax : + 91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com Corporate Relationship Department National Stock Excha
Read more →RDYReport of Independent Registered Public Accounting Firm The Board of Directors and Shareholders Dr. Reddy's Laboratories Limited: We have reviewed the condensed consolidated interim statements of financial position of Dr
Report of Independent Registered Public The Board of Directors and Shareholders Dr. Reddy's Laboratories Limited: We have reviewed the condensed consolidated interim statements of financial position of Dr. Reddy's Laboratories Limited and its subsidiaries ("the Company") as
Read more →RDYDR. REDDY'S LABORATORIES LTD. INVESTOR RELATIONS MEDIA RELATIONS 8-2-337, Road No. 3, Banjara Hills, SAUNAK SAVLA CALVIN PRINTER Hyderabad - 500034. Telangana, India. saunaks@drreddys.com calvinprinter@drreddys.c
CONTACT DR. REDDY'S LABORATORIES LTD. INVESTOR RELATIONS MEDIA RELATIONS 8-2-337, Road No. 3, Banjara Hills, SAUNAK SAVLA CALVIN PRINTER Hyderabad - 500034. Telangana, India. saunaks@drreddys.com calvinprinter@drreddys.com (Ph: +91-40-4900 2135) (Ph: +91-40-4900 2121) Reddy's
Read more →RDYDr. Reddy s Laboratories Ltd. 8-2-337, Rood No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com
Dr. Reddy s Laboratories Ltd. 8-2-337, Rood No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel : +91 40 4900 2900 Fax : +91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com National Stock Exchange of India Ltd. New York
Read more →RDYDR. REDDY S LABORATORIES LTD. INVESTOR RELATIONS MEDIA RELATIONS 8-2-337, Road No. 3, Banjara Hills, SAUNAK SAVLA CALVIN PRINTER Hyderabad 500034. Telangana, India. saunaks@drreddys.com calvinprinter@drreddys.com
CONTACT DR. REDDY S LABORATORIES LTD. INVESTOR RELATIONS MEDIA RELATIONS 8-2-337, Road No. 3, Banjara Hills, SAUNAK SAVLA CALVIN PRINTER Hyderabad 500034. Telangana, India. saunaks@drreddys.com calvinprinter@drreddys.com (Ph: +91-40-49002135) (Ph: +91-40- 49002121) Dr
Read more →RDYAurigene, a wholly owned subsidiary of Dr Reddy s, and Curis announce CA-170 program update following data presented at ESMO 2017 Results from 34 patients demonstrate positive safety profile and support dec
Aurigene, a wholly owned subsidiary of Dr Reddy s, and Curis announce CA-170 program update following data presented at ESMO 2017 Results from 34 patients demonstrate positive safety profile and support decision to expand Development Aurigene and Curis Plan Clinical Trial of
Read more →RDYDr. Reddy s Laboratories announces the launch of Bupropion Hydrochloride Extended-Release Tablets, USP (XL) in the U.S. Market Hyderabad, India
Dr. Reddy s Laboratories announces the launch of Bupropion Hydrochloride Extended-Release Tablets, USP (XL) in the U.S. Market Hyderabad, India and Princeton, NJ, USA. September 06, 2017 Dr. Reddy s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that
Read more →RDYDr. Reddy s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com
Surveillance Department BSE Limited Dalal Street, Fort Mumbai 400 001 National Stock Exchange of India Ltd. Exchange Plaza Bandra-Kurla Complex, Bandra (East), Mumbai 400 051 Fax Nos.: 22-22723121 / 22723719 / 22722037 / 22722039 Fax Nos.: 022-26598120/ 26598237/ 265982
Read more →RDYDr. Reddy s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel: +91 40 4900 2900 Fax: +91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com
Dr. Reddy s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel: +91 40 4900 2900 Fax: +91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com Corporate Relationship Department BSE Limited Dal
Read more →RDYReport of Independent Registered Public Accounting Firm The Board of Directors and Shareholders Dr. Reddy s Laboratories Limited: We have reviewed the accompanying condensed consolidated interim statements of financial p
Report of Independent Registered Public Accounting Firm The Board of Directors and Shareholders Dr. Reddy s Laboratories Limited: We have reviewed the accompanying condensed consolidated interim statements of financial position of Dr. Reddy s Laboratories Limited and its subs
Read more →RDYDr. Reddy s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com 2
Exchange of India Limited New York Stock Exchange Scrip Code: 500124 (BSE), DRREDDY (NSE), RDY(NYSE) Sub.: Outcome of 33rd Annual General Meeting & Voting This is with reference to our earlier letter dated 5 July 2017 regarding the 33rd Annual General Meeting (AGM) of the Co
Read more →RDYDR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS MEDIA RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-49002135) CALVIN PRINTER ca
CONTACT DR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS MEDIA RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-49002135) CALVIN PRINTER calvinprinter@drreddys.com (Ph: +91-40- 49002121) CONT
Read more →RDYDr. Reddy s Laboratories Limited NOTICE OF ANNUAL GENERAL MEETING Notice is hereby given that the 33rd annual general meeting (AGM) of the members of Dr. Reddy s Laboratories Limited (CIN: L85195TG1984PLC004507) will be
Dr. Reddy s Laboratories Limited NOTICE OF ANNUAL GENERAL MEETING Notice is hereby given that the 33rd annual general meeting (AGM) of the members of Dr. Reddy s Laboratories Limited (CIN: L85195TG1984PLC004507) will be held on Friday, 28 July 2017 at 9.30 AM at the Kaveri Bal
Read more →RDYDr. Reddy s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com
Dr. Reddy s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email: mail@drreddys.com www.drreddys.com June 15, 2017 Surveillance Department National Stock E
Read more →RDYDr. Reddy s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com
Dr. Reddy s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN : L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email : mail@drreddys.com www.drreddys.com Corporate Relationship Department Na
Read more →RDYDr. Reddy s Laboratories announces the launch of Bivalirudin for Injection in the U.S. Market Hyderabad, India
Dr. Reddy s Laboratories announces the launch of Bivalirudin for Injection in the U.S. Market Hyderabad, India and Princeton, NJ, USA. June 06, 2017 Dr. Reddy s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launched Bivalirudin for Inject
Read more →RDYDr. Reddy s Laboratories Limited to present at the Jefferies 2017 Global Healthcare Conference Hyderabad, India, June 5 th , 2017 For Immediate Release Hyderabad, India and Princeton, NJ, USA. June 5 th , 2017 Dr. Reddy
Dr. Reddy s Laboratories Limited to present at the Jefferies 2017 Global Healthcare Conference Hyderabad, India and Princeton, NJ, USA. June 5th, 2017 Dr. Reddy s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced that the Company will be presenting at the Jeffer
Read more →RDYDr. Reddy s Laboratories announces USFDA approval for the launch of Doxorubicin Hydrochloride Liposome Injection in the U.S. Market Hyderabad, India
Hyderabad, India and Princeton, NJ, USA. May 17 2017 Dr. Reddy s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has received approval from the U.S. Food and Drug Administration (USFDA) to launch Doxorubicin Hydrochloride Liposome Injection, a th
Read more →RDYDR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS MEDIA RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-4900 2135) CALVIN PRINTER c
CONTACT DR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS MEDIA RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-4900 2135) CALVIN PRINTER calvinprinter@drreddys.com (Ph: +91-40-4900 2121) Dr.
Read more →RDYDR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. CONTACT INVESTOR RELATIONS MEDIA RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-49002135) CALVIN PRINTER ca
DR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. CONTACT INVESTOR RELATIONS MEDIA RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-49002135) CALVIN PRINTER calvinprinter@drreddys.com (Ph: +91-40-49002121) Dr. Red
Read more →RDYDr. Reddy s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com
Dr. Reddy s Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel :+91 40 4900 2900 Fax :+91 40 4900 2999 Email :mail@drreddys.com www.drreddys.com Corporate Relationship Department National Stock Excha
Read more →RDYReport of Independent Registered Public Accounting Firm The Board of Directors and Shareholders Dr. Reddy s Laboratories Limited: We have reviewed the accompanying condensed consolidated interim statement of financial po
Report of Independent Registered Public Accounting Firm The Board of Directors and Shareholders Laboratories Limited: We have reviewed the accompanying condensed consolidated interim statement of financial position of Dr. Reddy s Laboratories Limited and its subsidiaries ( th
Read more →RDYDR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. CONTACT INVESTOR RELATIONS MEDIA RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-4900 2135) CALVIN PRINTER c
DR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. CONTACT INVESTOR RELATIONS MEDIA RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-4900 2135) CALVIN PRINTER calvinprinter@drreddys.com (Ph: +91-40-4900 2121) Dr. R
Read more →RDYDr. Reddy s to release Q3 FY17 results on
Dr. Reddy s Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) will announce results for the Third Quarter and 9 months ended December 31, 2016 on Saturday, February 4, 2017 after the Board Meeting. The results will be available on the Company s website www.drreddys.com Event
Read more →RDYDr. Reddy s Laboratories announces the launch of Nystatin and Triamcinolone Acetonide Cream, USP in the U.S. Market Hyderabad, India, 05 December 2016 For Immediate Release Hyderabad, India and Princeton, NJ, USA. 05 Dec
Dr. Reddy s Laboratories announces the launch of Nystatin and Triamcinolone Acetonide Cream, USP in the U.S. Market Hyderabad, India and Princeton, NJ, USA. 05 December 2016 Dr. Reddy s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has launche
Read more →RDYDR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad 500034. Telangana, India. CONTACT INVESTOR RELATIONS MEDIA RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40- 49002135) CALVIN PRINTER cal
DR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad 500034. Telangana, India. CONTACT INVESTOR RELATIONS MEDIA RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40- 49002135) CALVIN PRINTER calvinprinter@drreddys.com (Ph: +91-40- 49002121) Dr. Red
Read more →RDYDr. Reddy s Laboratories announces new strategic deal with Gland Pharma in the U.S. Market Hyderabad, India
Dr. Reddy s Laboratories announces new strategic deal with Gland Pharma in the U.S. Market Hyderabad, India and Princeton, NJ, USA. October 26, 2016 Dr. Reddy s Laboratories Ltd (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has entered into a strategic collabo
Read more →RDYDR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-49002135) MEDIA RELATIONS CALVIN PRINTER ca
CONTACT DR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS SAUNAK SAVLA saunaks@drreddys.com (Ph: +91-40-49002135) MEDIA RELATIONS CALVIN PRINTER calvinprinter@drreddys.com (Ph: +91-40- 49002121) Dr. Red
Read more →RDYDR. REDDY S LABORATORIES LTD. INVESTOR RELATION S MEDIA RELATION S 8-2-337, Road No. 3, Banjara Hills, SAUNAKS SAVLA CALVIN PRINTER Hyderabad - 500034. Telangana, India. saunaks@drreddys.com (Ph: +91-40-49002135)
CONTACT DR. REDDY S LABORATORIES LTD. INVESTOR RELATION S MEDIA RELATION S 8-2-337, Road No. 3, Banjara Hills, SAUNAKS SAVLA CALVIN PRINTER Hyderabad - 500034. Telangana, India. saunaks@drreddys.com (Ph: +91-40-49002135) calvinprinter@drreddys.com (Ph: +91-40- 49002121)
Read more →RDYDr. Reddy s Laboratories launches Nitroglycerin sublingual tablets USP in the U.S. Market Hyderabad, India
In addition to statements which are forward-looking by reason of context, the words may , will , should , expects , plans , intends , anticipates , believes , estimates , predicts , potential , or continue and similar expressions identify forward-looking statements. Actual result
Read more →RDYDr. Reddy s completes acquisition of product portfolio from TEVA Hyderabad, India
In addition to statements which are forward-looking by reason of context, the words may , will , should , expects , plans , intends , anticipates , believes , estimates , predicts , potential , or continue and similar expressions identify forward-looking statements. Actual result
Read more →RDYDR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. CONTACT INVESTOR RELATIONS MEDIA RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CALVIN PRINTER ca
DR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. CONTACT INVESTOR RELATIONS MEDIA RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CALVIN PRINTER calvinprinter@drreddys.com (Ph: +91-40- 49002121) Dr. Re
Read more →RDYDR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS MEDIA RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CALVIN PRINTER ca
CONTACT DR. REDDY S LABORATORIES LTD. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500034. Telangana, India. INVESTOR RELATIONS MEDIA RELATIONS KEDAR UPADHYE kedaru@drreddys.com (Ph: +91-40-66834297) CALVIN PRINTER calvinprinter@drreddys.com (Ph: +91-40- 49002121) Dr. R
Read more →RDYDr. Reddy s Laboratories Limited announces filing of Annual Report on Form 20-F Hyderabad, India
Dr. Reddy s Laboratories Limited announces filing of Annual Report on Form 20-F Hyderabad, India, June 24, 2016: Dr. Reddy s Laboratories Limited (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced that its Annual Report on Form 20-F, containing its annual consolidated fina
Read more →RDYRef: II/CA/COM/20939/2016
The Company Secretary Dr. Reddys Laboratories Limited Sub: Buy-back (open market purchase) As per the corporate action(s) executed by your R&T Agent/Registry Division viz; Bigshare Services Pvt. Limited, Equity Shares were credited/debited to the account(s) in the NSDL system
Read more →RDYDr. Reddy s to acquire product portfolio from TEVA for US Market Hyderabad, India
Dr. Reddy s to acquire product portfolio from TEVA for US Market Hyderabad, India, June 11, 2016 For Immediate Release Hyderbad, India and Princeton, USA Dr. Reddy s Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) has entered into a definitive agreement with Teva Pharmaceutic
Read more →RDYDr. Reddy s Laboratories Ltd. 8-2-337, Road No.3, Banjara Hills, Hyderabad 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel: +9140 4900 2900 Fax: +9140 4900 2999 Email: mail@drreddys.com www.drreddys.com
With reference to the captioned subject matter, the Company hereby submits the daily report pursuant to Regulation 15(i) of the SEBI (Buy Back of Securities) Regulations, 1998 regarding equity shares bought back on June 6, 2016: Name of the Broker Number of Equity Shares Bough
Read more →RDYHyderabad, India and Princeton, NJ, USA.
Hyderabad, India and Princeton, NJ, USA. June 1, 2016: Dr. Reddy s Laboratories announced today that its US subsidiary, Promius Pharma, LLC, U.S. (BSE: 500124, NSE: DRREDDY, NYSE: RDY), launched Sernivo (betamethasone dipropionate) Spray, 0.05% in the U.S. Sernivo Spray, a presc
Read more →RDYDr. Reddy s Laboratories Ltd. 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel: +9140 4900 2900 Fax: +9140 4900 2999 Email: mail@drreddys.com www.drreddys.com
Dr. Reddy s Laboratories Ltd. 8-2-337, Road No.3, Banjara Hills, Hyderabad - 500 034, Telangana, India. CIN: L85195TG1984PLC004507 Tel: +9140 4900 2900 Fax: +9140 4900 2999 Email: mail@drreddys.com www.drreddys.com With reference to the captioned subject matter, the
Read more →RDYDr. Reddy s enters the branded consumer health arena through the acquisition of six OTC brands Hyderabad, India
Dr. Reddy s enters the branded consumer health arena through the acquisition of six OTC brands Hyderabad, India and Princeton, NJ, USA Dr. Reddy s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY) today announced the acquisition of an eminent portfolio of over-the-count
Read more →RDYDR. REDDY S LABORATORIES LTD. INVESTOR RELATIONS MEDIA RELATIONS 8-2-337, Road No. 3, Banjara Hills, KEDAR UPADHYE CALVIN PRINTER Hyderabad - 500034. Telangana, India. kedaru@drreddys.com (Ph: +91-40-66834297) ca
CONTACT DR. REDDY S LABORATORIES LTD. INVESTOR RELATIONS MEDIA RELATIONS 8-2-337, Road No. 3, Banjara Hills, KEDAR UPADHYE CALVIN PRINTER Hyderabad - 500034. Telangana, India. kedaru@drreddys.com (Ph: +91-40-66834297) calvinprinter@drreddys.com (Ph: +91-40- 49002121) Dr.
Read more →RDYZEMBRACE TM SymTouch TM (sumatriptan injection) 3 mg, approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the U.S. Hyderabad, India
ZEMBRACETM SymTouchTM (sumatriptan injection) 3 mg, approved by the FDA in January 2016 for the acute treatment of migraine with or without aura in adults, is now commercially available in the U.S. Hyderabad, India and Princeton, NJ, USA. April 19, 2016 Promius Pharma LLC, a
Read more →RDYDR. REDDY S LABORATORIES LIMITED Registered Office : 8-2-337, Road No.3, Banjara Hills, Hyderabad 500 034, Telangana, India CIN : L85195TG1984PLC004507, Tel : +91 40 4900 2900, Fax : +91 40 4900 2999 Website : www.drredd
DR. REDDY S LABORATORIES LIMITED Registered Office : 8-2-337, Road No.3, Banjara Hills, Hyderabad 500 034, Telangana, India CIN : L85195TG1984PLC004507, Tel : +91 40 4900 2900, Fax : +91 40 4900 2999 Website : www.drreddys.com, E-mail : mail@drreddys.com OF THE SHAREHOLDERS/B
Read more →RDYHyderabad, India
Hyderabad, India, March 31, 2016 - Dr. Reddy s Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) announced today that it has entered into a licensing agreement with Eisai Co., Ltd, Japan by which Dr. Reddy s will be granted exclusive worldwide development and commercialization
Read more →RDYDr. Reddy s Laboratories and XenoPort Enter Into a U.S. Licensing Agreement for XP23829 Hyderabad, India, and Santa Clara, CA
Dr. Reddy s Laboratories and XenoPort Enter Into a U.S. Licensing Agreement for XP23829 Hyderabad, India, and Santa Clara, CA March 28, 2016 Dr. Reddy s Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY) and XenoPort, Inc. (NASDAQ: XNPT) announced today that they have entered
Read more →RDYDr. Reddy s Laboratories Limited Q3 FY16 Earnings Call Transcript Page 1 of 21 Dr. Reddy s Laboratories Limited
Dr. Reddy s Laboratories Limited Earnings Call Transcript Dr. Reddy s Laboratories Limited Good Morning and Good Evening to all of you. Thank you for joining us today for Dr. Reddy s Earnings Call for Third Quarter of Fiscal 2016. Earlier during the day, we have released our
Read more →RDYNSE: DRREDDY; BSE: 500124; NYSE: RDY The Board of Directors of the Company in their meeting held on 17 th February, 2016 has approved a proposal to buyback Equity Shares of the Company, subject to approval by the shareho
NSE: DRREDDY; BSE: 500124; NYSE: RDY The Board of Directors of the Company in their meeting held on 17th February, 2016 has approved a proposal to buyback Equity Shares of the Company, subject to approval by the shareholders, for an aggregate amount not exceeding Rs. 15,694 mil
Read more →RDYHyderabad, India, & Princeton, NJ, USA.
Hyderabad, India, & Princeton, NJ, USA. February 01, 2016, Dr. Reddy s Laboratories (BSE: 500124, NSE: DRREDDY, NYSE: RDY), announced today the U.S. Food and Drug Administration (US FDA) tentative approval for Zenavod (doxycycline) Capsules, 40 mg. Zenavod is a tetracycline-clas
Read more →Competitive Position
How RDY ranks across every disease it competes inCompetitive Position is a premium feature
See how RDY ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial